发明名称 METHOD FOR IMMUNOTHERAPY OF CEREBRAL MALIGNANT TUMORS
摘要 FIELD: medicine, oncology. ^ SUBSTANCE: after removing malignant cerebral tumor one should conduct successive course of: cytokinotherapy consisting of 3 intramuscular injections of leukineferon at 48-h-long interval, adaptive immunotherapy with lymphokine-activated killer cells (LAKC) generated in the presence of recombinant interleukin-2 (IL-2). Moreover, LAKC should be introduced into the channel of removed tumor in combination with IL-2 as 2 procedures at 24-h-long interval. Then comes the course of adaptive immunotherapy with cytotoxic lymphocytes (CTL) generated due to cultivating patient's mononuclear blood cells together with dendritic cells loaded with a tumor antigen, in the presence of recombinant IL-2 to be introduced in combination with it into the channel of removed tumor as 2 procedures at 48-h-long interval. For obtaining dendritic cells in patients before operation it is necessary to isolate monocytes to cultivate with granulocytic-macrophageal colony-stimulating factor and interferon-alpha at maturating dendritic cells in the presence of monocytic conditioned medium and incubation of dendritic cells in the presence of tumor antigenic material for their loading with a tumor antigen. After immunotherapy with CTL on should conduct the course of vaccinotherapy with dendritic cells loaded with a tumor antigen in combination with subcutaneous injections of IL-2. The method enables to induce high specific anti-tumor immune response along with improved quality of life and prolonged duration of relapse-free period. ^ EFFECT: higher efficiency of immunotherapy. ^ 2 cl, 2 ex
申请公布号 RU2262941(C2) 申请公布日期 2005.10.27
申请号 RU20040100550 申请日期 2004.01.05
申请人 发明人 CHERNYKH E.R.;LEPLINA O.JU.;OSTANIN A.A.;NIKONOV S.D.;STUPAK V.V.;KOZLOV JU.P.
分类号 A61K35/16;A61K38/20;A61K38/21;A61P35/00 主分类号 A61K35/16
代理机构 代理人
主权项
地址